Drug Profile


Alternative Names: CHR-2845; Tefinostat tartrate

Latest Information Update: 18 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chroma Therapeutics
  • Developer Cardiff University; Chroma Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia
  • Phase I/II Inflammation
  • No development reported Haematological malignancies; Lymphoma

Most Recent Events

  • 18 Oct 2018 Tefinostat is still in phase I/II trials for Inflammation (associated with cancer in patients with liver cancer) in United Kingdom (EudraCT2012-000326-22)
  • 24 Jun 2018 Biomarkers information updated
  • 24 Sep 2015 Phase-II clinical trials in Chronic myelomonocytic leukaemia in United Kingdom (PO) (ISRCTN17394489)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top